Other members of the Consortium include the University of Maryland, Baltimore, the University of Illinois at Chicago, Indiana University at Indianapolis, the Armed Forces Radiobiology Research Institute at Bethesda, Fast Track Drugs and Biologics LLC, Aotech, LLC, and Information Management Consultants, Inc.
EpiStem is a biotechnology company commercialising adult stem cells in the areas of oncology and gastrointestinal diseases as well as cosmeceutical applications. EpiStem develops innovative therapeutics and diagnostic biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. EpiStem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.
EpiStem operates two distinct business divisions, Contract Research Services and Novel Therapies.
Contract Research Services
Contract Research Services provides specialised preclinical efficacy testing primarily for drug development companies on a fee for service basis. This division on a standalone basis is cash generative and profitable with a five-year track record of providing testing services to over 72 international company clients primarily in Europe and the United States.
Novel Therapies is focused on developing its own innovative
therapeutics and diagnostic biomarkers. Through its discovery platform,
Novel Therapies has identified 250 potential drug candidates, of which a
subset will undergo further evaluation as stem cell regulators for the
Group's emerging drug development pipeline. Novel Thera
|SOURCE Epistem Ltd|
Copyright©2007 PR Newswire.
All rights reserved